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Abstract
Background
The electronic nose (e-nose) detects volatile organic compounds (VOCs) in exhaled air. We
hypothesized that the exhaled VOCs print is different in stable vs. exacerbated patients with
chronic obstructive pulmonary disease (COPD), particularly if the latter is associated with
airway bacterial infection, and that the e-nose can distinguish them.
Methods
Smell-prints of the bacteria most commonly involved in exacerbations of COPD (ECOPD)
were identified in vitro. Subsequently, we tested our hypothesis in 93 patients with ECOPD,
19 of them with pneumonia, 50 with stable COPD and 30 healthy controls in a cross-sec-
tional case-controlled study. Secondly, ECOPD patients were re-studied after 2 months if
clinically stable. Exhaled air was collected within a Tedlar bag and processed by a Cynar-
ose 320 e-nose. Breath-prints were analyzed by Linear Discriminant Analysis (LDA) with
“One Out” technique and Sensor logic Relations (SLR). Sputum samples were collected for
culture.
Results
ECOPD with evidence of infection were significantly distinguishable from non-infected
ECOPD (p = 0.018), with better accuracy when ECOPD was associated to pneumonia. The
same patients with ECOPD were significantly distinguishable from stable COPD during fol-
low-up (p = 0.018), unless the patient was colonized. Additionally, breath-prints from COPD
patients were significantly distinguished from healthy controls. Various bacteria species
were identified in culture but the e-nose was unable to identify accurately the bacteria smell-
print in infected patients.
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Conclusion
E-nose can identify ECOPD, especially if associated with airway bacterial infection or
pneumonia.
Introduction
Exacerbations of Chronic Obstructive Pulmonary Disease (ECOPD) are important events in
the natural history of the disease because they influence disease progression, morbidity [1] and
mortality [2]. The diagnosis of ECOPD relies on the increase of respiratory symptoms reported
by the patient with or without an increase in sputum volume or purulence [3, 4]. Hence,
despite the high sanitary burden of ECOPD, their diagnosis and treatment are currently empir-
ical [3, 5].
ECOPD are characterized by a burst of pulmonary and systemic inflammation [6], generally
believed to be the result of viral and/or bacterial airway infections [7, 8]. However, potential
pathogenic micro-organisms (PPM) can be recovered during ECOPD in only a proportion of
patients (30% of sputum cultures and 50% of bronchial secretion cultures) [9, 10]. These per-
centages increase slightly (59%) if quantitative PCR is used [11]. Besides, PPB can also be
recovered in a proportion of clinically stable COPD patients [8]. Therefore, novel methods
capable of identifying more precisely the role of infection during ECOPD are needed. They can
contribute to improve the quality of care provided to these patients since they may foster a
more appropriate use of antibiotic therapy under these circumstances.
Over the past decade there has been increasing interest on the potential diagnostic value of
volatile organic compounds (VOCs) exhaled in human breath [12]. The electronic nose (e-
nose) constitutes an emerging non-invasive technique capable of detecting and differentiating
VOCs patterns (“smell prints”) in humans (“breatheomics”) [13, 14]. Recent studies have
shown that the e-nose can reliably identify patients with bronchial asthma [15], lung cancer
[16], bacterial pneumonia [17] and bacterial sinusitis [18], as well as to identify and classify
various bacterial species cultured in vitro [19, 20]. In a pilot study, our group previously
showed that the e-nose can detect bacterial colonization in clinically stable patients with
COPD [16, 21].
Considering all these previous observations we hypothesized that the VOCs smell prints
will be different during ECOPD vs. clinical stability, will discriminate infectious vs. non-infec-
tious ECOPD or pneumonia, and will identify the specific bacterial species present in the air-
ways during ECOPD. Accordingly, in this study we sought to: (1) determine the sensitivity,
specificity, positive predictive value and negative predictive value of the e-nose in the bacterio-
logical diagnosis of ECOPD with or without pneumonia which is our primary objective; (2)
investigate whether the VOCs smell print changes in the transition from ECOPD to clinical
stability; (3) explore the feasibility of developing a system capable of identifying and establish
the presence of bacterial infection in an exhaled air sample by analysing libraries of bacteria
previously identified and characterized in vitro.
Methods
Study design and Ethics
The current study was divided into 2 parts. The first part is a cross-sectional descriptive, case-
controlled study that included COPD patients hospitalized because of ECOPD (with and
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without pneumonia) and clinically stable COPD patients as well as healthy control subjects.
The second part is a longitudinal study that compared ECOPD patients (1st visit) and the same
ones at clinical stability two months later (2nd visit); Fig 1. The sample size was calculated using
a two sided Fisher exact’s test for independent case-control study with a significance level (α)
of 0.05 and power of test of 80% considering that PPM growth in sputum could be detected in
30% of the patients with ECOPD [22, 23] and based on our pilot study published by Sibila et al
[21]. All the patients were recruited from the ward (ECOPD), out-patient clinic (stable COPD)
and lung function laboratory (controls) at Son Espases University Hospital in Palma de
Mallorca (Spain). All of the participants signed their informed consent, and the study protocol
was approved by the local Ethics Committee of Balearic Islands.
Study population
COPD was defined by a post-bronchodilator FEV1/FVC<70% and history of tobacco con-
sumption>10 pack-year following GOLD recommendations [5]. We included in the study
patients with a diagnosis of ECOPD according to GOLD guidelines [5] defined by acute wors-
ening of daily respiratory symptoms-beyond the normal day to day variations- that required a
Fig 1. Flow chart of the studied population at every visit.
doi:10.1371/journal.pone.0135199.g001
E-Nose and Infection during COPD Exacerbations
PLOS ONE | DOI:10.1371/journal.pone.0135199 September 9, 2015 3 / 16
change in medication; ECOPD patients that had associated pneumonia proved by the presence
of new infiltrates on chest radiography [24] were also included. These patients were compared
with clinically stable COPD defined by absence of an exacerbation requiring antibiotic or ste-
roid therapy within 30 days prior to inclusion and control healthy subjects with normal lung
function recruited from our pulmonary function unit (Fig 1). Infective episode of ECOPD was
defined by the presence of PPM growth in sputum culture (see below) in patients fulfilling the
previous definition of ECOPD. Colonization was defined by the presence of PPM growth in
stable COPD patients. Patients with no PPM growth in sputum culture were considered non-
infected for the study purpose. All ECOPD were followed up and studied again 2 months after
exacerbation, when clinically stable.
Patients with a history of asthma, primary bronchiectasis, lung cancer, active tuberculosis,
interstitial lung diseases, active infection other than those of pulmonary origin including upper
airways infection, and those who had taken antibiotics in the last seven days were excluded
from the study.
Characterization of participants. We obtained in all patients a detailed clinical history
(including age, gender, smoking history, relevant comorbid conditions, number of previous
exacerbations, and drug history), a chest X-ray, pulmonary function measurements (including
forced spirometry, carbon monoxide diffusing capacity (DLCO) and static lung volumes) fol-
lowing international recommendations [25] and using reference values of a Mediterranean
population [26]. Chest Computed Tomography (CT) was performed if indicated clinically.
Spontaneous sputum and exhaled air samples were collected consecutively in all patients.
E-nose measurements
Exhaled breath gas was collected for e-nose assessment as previously described [15, 27]. Briefly,
the exhaled gas from all subjects −as well as clear air collected from the same environment as
baseline reference− were collected in a 5 Liters Tedlar bag after 3 minutes of tidal breathing
through a Hans-Rudolph valve with an expiratory silica reservoir exposed to dry air and an
inspiratory filter. The e-nose device (Cyranose 320; Smith Detections, Pasadena, CA), with 32
organic polymeric nano-composite sensor arrays, was then connected to the Tedlar bag as five
to six measurements of the each sample were obtained over 5 minutes duration. Changes in the
nanosensor’s electrical resistance between clear air and subjects’ exhaled breath generate a
breath-print VOCs profile. As a difference from previous publications, the resistance value was
monitored during the whole measuring time using several parameters (as slope values) to gen-
erate the breath-print profile. Transcutaneous oxygen saturation (SaO2) was continuously
monitored during the procedure.
Sputum culture
Spontaneous sputum samples were collected within 24 hours of presentation of ECOPD symp-
toms as well as from clinically stable COPD cases. All the sputum samples were collected in
sterile containers and transferred to the microbiological laboratory within 2 hours of collection
for Gram staining and bacterial culture. All the sputum samples were classified according to
Murray-Washington criteria, thus grade IV (10–25 epithelial cells and> 25 leucocytes per
field) and grade V (< 10 epithelial cells and> 25 leucocytes per field) were cultured quantita-
tively and a bacterial load106 colony forming units (CFU)/ml was considered as significant.
Culture was performed in non-selective (sheep blood agar, chocolate agar) and selective media
(MacConkey agar) at 37°C for 48 hours in 5% CO2, and bacterial species identification was
conducted biochemically (Microscan, Siemens). The identified microorganisms were classified
as potentially pathogenic microorganisms (PPM) including Streptococcus pneumoniae,
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Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureusmethicillin suscepti-
ble or resistant,Moraxella catarrhalis, and Gram negative-bacilli, and non-PPM included Can-
dida spp., Streptococcus viridans, Neisseria spp., Staphylococcus epidermidis and
Corynebacterium spp.
In vitro e-nose learning
To let the e-nose learn the breath print of specific bacteria, at least one representative clinical
isolate for each species included in the potentially pathogenic microorganism group was ana-
lyzed by using the e-nose, specifically 3 S. pneumoniae, 3H. influenzae, 3 P. aeruginosa, 1 S.
aureus, 1M. catarrhalis, and 1 E.coli isolate were included (Table A in S1 File). These bacteria
were cultured on appropriate non-selective media (sheep blood agar and/or chocolate agar) at
37°C for 18–24 hours in 5% CO2 on Petri plates. Then, plates were exposed to e-nose inhala-
tion to build up a library of VOCs pattern for each bacteria following previously described
methodology [19]. Briefly, filtered air from a Tedlar bag was introduced into the close plates
through a hole located in one extreme of the plate cover; then the VOC were extracted and
delivered to the e-nose through a second hole located in the other side of the plate cover (Fig
2). Several exposition times were tried and finally an exposition time of about 6 minutes was
selected as it coincides with no changes in the slope of the sensors. The e-nose sensors regis-
tered continuously the relative changes in resistance due to volatile organic compounds in the
headspace (i.e., the space over the agar media in the Petri plates) using mathematical algo-
rithms for each bacterium independently on the culture media used. Each measure was com-
pared with a reference measure to obtain the sensor readout, being the reference a non-
inoculated Petri plate. For each plate of the different bacterial strains, the measurement was
repeated eight times with a total duration of 20 minutes.
Data analysis
Results are presented as mean ± standard deviation (SD) for quantitative variables or absolute
numbers and relative frequencies for categorical variables. Comparisons between different
groups were analysed with the Chi Square, Mann-Whitney or Kruskal-Wallis tests as appropri-
ate. MedCalc (version 9.2.1.0, Acacialaan 22, B-8400 Ostend, Belgium) was used for analysis.
Breath-print data from ECOPD patients (infected and non-infected), ECOPD with associ-
ated pneumonia, stable COPD as well as healthy controls were analysed using two methods:
Linear Discriminant Analysis (LDA) for comparison between the different groups [15] and
Sensor Logic Relations (SLR), a new data management approach to identify different microor-
ganisms in exhaled breath. Briefly, instead of considering the values of the relative resistance to
generate the breath-print for each patient, breath-print is built with Logic Relations between
the Resistor values as “Resistor 2 value is greater than Resistor 5”. This technique is adopted to
consider the relative sensitivity of two sensors to a certain VOC profile (additional information
provided in S1 File). The results were expressed as success classification ratio [28] as well as
sensitivity and specificity.
Results
Population characteristics
We included in the study 185 subjects, 93 of whom had a diagnosis of ECOPD (19 of them
with associated pneumonia), fifty patients with clinically stable COPD and 30 control healthy
subjects (Fig 1).
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Table 1 presents the main demographic and clinical characteristics of the population stud-
ied. COPD patients-either ECOPD or clinically stable- were mostly males, with a similar age
and proportion of co-morbidities. Cumulative smoking exposure (pack-years) was higher in
COPD patients than healthy controls; however the ex-smokers constituted the highest
Fig 2. Identification of bacteria in vitro. Experimental setting.
doi:10.1371/journal.pone.0135199.g002
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proportion among all groups (Table 1). COPD patients had moderate to severe airflow limita-
tion and reduced DLCO whereas controls had normal lung function (Table 1). Previous admis-
sions were higher in the ECOPD group compared to stable COPD patients and healthy
controls. Chest CT scanners were available for 108 participants. Emphysematous changes were
detected in> 50% of all COPD patients and in 13.3% of smoker controls. Bronchiectasis was
detected only among COPD groups being more prevalent in ECOPD either with or without
associated pneumonia (20.5% and 15.7% respectively; Table 1) than stable COPD patients.
Microbiological cultures
Forty-two patients (45%) with ECOPD and seventeen (34%) of stable COPD had PPM in the
baseline characterization (Table 1 and S1 Fig A in S1 File). Sputum samples did not show
growth of PPM in 19% of exacerbation episodes and were considered as non-infective episodes.
Pseudomonas aeruginosa was the most commonly isolated microorganism (34%) followed by
Haemophilus influenzae (13.6%), Streptococcus Pneumoniae (10.2%),Moraxella catarrhalis
Table 1. Demographic, clinical and functional characteristics of the population studied.
Variable ECOPD
(n = 74)
ECOPD with
pneumonia(n = 19)
Stable COPD
(n = 50)
p
value$
Control non-COPD
(n = 30)
p value#
Age (years) 68 ± 7.8 70 ± 9.3 68.6 ± 9.5 0.699 63.8± 12.4 0.291
Gender (M/F); n 53/21 16/3 38/12 0.534 13/17 0.033*
Smoking; n (%)
Current
smoker
33 (44.6) 11 (57.9) 24 (48) 4 (13.3)
Ex-smoker 41 (55.4) 8 (42.1) 26 (52) 0.659 14 (46.7) <0.0001*
Non-smoker 12 (40) <0.0001*
Pack/years 58.4±26.1 58.6 ± 29.4 61.6 ± 37.4 0.976 15.5± 18.3 <0.0001*
Comorbidity; n (%) 57 (77) 12 (63.2) 42 (84) 0.427 20 (66.7) 0.743
Previous admission 3.9 ± 3.8 3.1 ± 3.3 1.8 ± 2.9 0.002* 0.13± 0.35 <0.0001*
Lung Function
FEV1/FVC, % 43.2 ±11.9 44.1 ±13.02 47.1 ±13.7 0.326 77.2 ± 5.5 <0.0001*
FEV1 (L) 1.2 ± 0.5 1.4 ± 0.5 1.6 ± 0.8 0.059 2.5 ± 0.7 <0.0001*
FEV1% ref. 47.3 ±16.7 53.9 ± 26 56.4 ± 22.6 0.166 98.5± 13.4 <0.0001*
FVC (L) 2.9 ± 0.9 3.1 ± 0.9 3.3 ± 0.97 0.249 3.2 ± 0.8 0.369
FVC % ref. 84.9 ± 22.6 90.7 ± 27.8 89.08 ± 18.8 0.603 98.5 ±12.5 0.007*
DLCO% ref. 46.6 ± 17.4 42.3 ± 22.2 50.9 ± 15.3 0.252 78.7 ± 9.5 <0.0001*
KCO% ref. 55.5 ± 24.03 40.1 ± 20.2 56.8 ± 14.3 0.074 79.4 ± 8.5 <0.0001*
Chest CT; n (%)
Emphysema 45 (60.8) 10 (52.6) 27 (54) 0.424 4 (13.3) 0.001*
Bronchiestasis 15 (20.2) 3 (15.7) 7 (14) 0.126 0 (0) 0.013*
sputum PPM; n (%) 34 (46) 8 (42.1) 17 (34) NA 0 (0) NA
SaO2 before breath
collection
93.9 ± 2.6 92.6 ± 3.3 94.9 ± 2.3 0.630 96.9 ± 0.9 0.773
SaO2 after breath
collection
93.2 ± 3.3 91.7 ± 3.02 95.4 ± 2.8 96.9 ± 1.3
Abbreviations: M/F: male/female, SAO2: oxygen saturation, NA: not assessed
$ p value for comparing between ECOPD, ECOPD with pneumonia and stable COPD
# p value for comparing the 4 groups.
doi:10.1371/journal.pone.0135199.t001
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(8.5%) then Staphylococcus aureusmethicillin susceptible (6.8%). Other species of bacteria
were isolated in 23.7% and Candida spp. was isolated in 10.2%.
Breath-print analysis
Exhaled-breath air collection during the ECOPD was safe without evidence of significant desa-
turation (p = 0.773, Table 1). The breath-prints from different COPD groups, either exacer-
bated or stable, were statistically discriminated from those obtained from healthy control
subjects (p< 0.05, Table 2).
ECOPD compared to stable COPD. In the cross-sectional analysis, breath-prints from
ECOPD were significantly distinguishable from stable COPD in case of absence of PPM
(p< 0.05; Table 2). Breath-prints of stable COPD patients with evidence of PPM, indicating
the presence of airway colonization, were not statistically different from infective ECOPD
(p = 0.074; Table 2).
In the longitudinal analysis, when the same patient was compared between exacerbation
and stability, the e-nose was able to distinguish breath-prints during ECOPD (1st visit) from
clinical stability (2nd visit) with a classification success ratio of 70%, sensitivity of 72% and spec-
ificity of 67% (Table 3). Stable COPD patients during the 2nd visit with evidence of PPM in spu-
tum were excluded from the analysis.
Pneumonia vs. non-pneumonia patients. Breath-prints from pneumonic ECOPD
were significantly distinguishable from stable COPD (classification success ratio: 86%, with
Table 2. Percentage of success ratio, sensitivity and specificity of the e-nose when comparing different groups of patients and controls in the
presence or absence of PPM in sputum.
Absence of PPM in sputum Presence of PPM in sputum
% of success ratio P Sn. Sp. % of success ratio P Sn. Sp.
Stable COPD vs Controls 72% 0.041 72% 70% 72% 0.005 70% %73
ECOPD vs Controls 74% 0.041 66% 80% 74% 0.001 68% 80%
Pneumonia vs Controls 87% 0.006 75% 90% 97% 0.005 88% 100%
ECOPD vs Pneumonia 86% 0.021 85% 86% 88% 0.005 91% 75%
ECOPD vs Stable COPD 76% 0.018 89% 48% 64% 0.074 57% 69%
Stable COPD vs Pneumonia 91% 0.021 95% 63% 86% <0.001 88% 75%
Sn: sensitivity, Sp: speciﬁcity.
doi:10.1371/journal.pone.0135199.t002
Table 3. Percentage of success ratio, sensibility and specificity of the e-nose when comparing different groups of patients based on the presence
(infected) or absence of PPM (not infected) in sputum and the exacerbated or stable condition.
% of success ratio p value Sn Sp
ECOPD (not infected-infected) 75% 0.018* 88% 60%
Pneumonia (not infected-infected) 100% 0.014* 100% 100%
ECOPD not infected–All groups infected 68% 0.026* 81% 59%
Infected by Pseudomonas–Other infections$ 56% 0.196 55% 56%
Infected by Pseudomonas–Not infected$ 68% 0.12 45% 70%
ECOPD with Pseudomonas–ECOPD not infected 69% 0.37 66% 71%
1st visit ECOPD– 2nd visit ECOPD 70% 0.068 74% 67%
$ Comparison done irrespective of patient group
* signiﬁcant p value < 0.05
doi:10.1371/journal.pone.0135199.t003
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sensitivity of 88% and specificity of 75%, p<0.001; Table 2). Further, the e-nose was able to sig-
nificantly discriminate the breath-prints of ECOPD associated with pneumonia from non-
pneumonic ECOPD regardless the presence of PPM (classification success ratio: 88%,
p = 0.005 with a sensitivity of 91% and specificity of 75%, Table 2, Fig 3A) or absence of PPM
(classification success ratio: 86%, p = 0.021; sensitivity = 85%, specificity = 86%; Table 2,
Fig 3B).
Infected vs. non-infected ECOPD. Among the ECOPD, the e-nose was able to discrimi-
nate breath-prints of infected patients versus non-infected patients with a classification success
ratio of 75% (p = 0.018), sensitivity of 88% and specificity of 60% (Table 3, Fig 3C). Moreover,
the percentage of success ratio was further improved in the pneumonic subgroup of ECOPD
(classification success ratio: 100%, p = 0.014; sensitivity and specificity of 100%; Table 3,
Fig 3D).
Fig 3. Two-dimensional principal component (PC) analysis plots: showing breath-prints discrimination between ECOPD versus ECOPDwith
pneumonia in case of infection (A) and absence of infection (B); ECOPDwith infection versus ECOPDwithout infection (C); ECOPD versus
ECOPDwith pneumonia without infection (D).
doi:10.1371/journal.pone.0135199.g003
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Bacterial identification in vitro. When comparing different species of bacteria in vitro,
the e-nose successfully discriminated the smell-print of two single species of bacteria (p<0.01,
Fig 4A–4D and Fig B in S1 File) using the LDAmethod. Upon analysing the same smell-prints
using SLR, one single species of bacteria (namely Pseudomonas aeruginosa, Streptococcus pneu-
moniae, Haemophilus influenzae, and Escherichia coli) was successfully discriminated versus all
other species with success ratios varying between 97 and 100%. Results upon single compari-
sons are provided in the on-line data supplement (Tables A, B, C, D and E in S1 File).
Bacterial identification in vivo. Despite the successful discrimination of bacteria species
in vitro, and the effective detection of infective ECOPD, the e-nose failed to identify a breath-
print of an individual bacterium in the infected patient when compared to a non-infected,
except for Haemophilus influenzae. Where different sensitive sensors obtained during in vitro
analysis (Tables B, C and D in S1 File) did not show similar sensitivity for analysing the same
bacterial species in vivo, this was not the case for Hemophilus influenza in which sensors 14, 15
Fig 4. Comparison between e-nose smell-prints among different species of bacteria. The graphs shows two-dimensional principal component (PC)
analysis plots showing smell-prints discrimination between 2 species of bacteria.
doi:10.1371/journal.pone.0135199.g004
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and 19 (Table 4 and Table D in S1 File) were linked to the presence of Hemophilus influenza
both in vitro and in vivo. Moreover, two different species of bacteria could be differentiated
with a success classification ratio of 82%, 95% and 100% using SLR analysis for Pseudomonas
aeruginosa vsHemophilus influenzae, Pseudomonas aeruginosa vs Escherichia coli andHemo-
philus influenza vs. Escherichia coli respectively (Table 4).
Discussion
In the current study, we described for the first time the validity of the e-nose technology in the
discrimination of infective episodes for ECOPD. Using simple mathematical algorithms the e-
nose distinguished specific breath-prints for infected ECOPD, and was able to detect when the
exacerbation was associated with pneumonia in comparison to non-infected ECOPD. Further,
it was able to identify single species of bacteria in vitro and still could differentiate between two
different groups of bacteria such as Pseudomonas aeruginosa andHemophilus influenzae in
vivo.
Previous studies
Sputum cultures for microorganism detection are considered to be of limited value in investi-
gating the etiology of ECOPD [9, 10]. Stolz et al [29] identified pathogenic bacteria in the spu-
tum samples in 36% to 38% in their randomized groups of ECOPD. Recently, Boixeda et al
[30] identified bacterial agent in only 24.1% of their cohort as an etiology of ECOPD, being
Pseudomonas aeruginosa and Haemophilus influenza the most common detected microorgan-
isms. Shykhon et al [31] and Lai et al [32] identified infection from the upper respiratory tract
using e-nose with an accuracy of 88.2%. Thaler et al [18] reported correct e-nose diagnosis of
bacterial sinusitis in 72% of their cohort. Further, Hanson et al [17] and Hockstein et al [33]
succeeded to detect bacterial infection in ICU patients with ventilator associated pneumonia
using e-nose with a prediction accuracy of more than 90%. Much more recently, Sibila et al
[21] reported 88% accuracy of e-nose in the identification of airway bacterial colonization in
stable COPD patients. Our results agree with these previous observations, as 45% of our spu-
tum samples during ECOPD showed PPM and we were able to differentiate them from non-
infective episodes with e-nose technology.
Interpretation of results
ECOPD is generally associated with a burst of airway inflammation [6, 34, 35]. This could be
the cause for a specific VOCs breath pattern in this condition, which is independent of the
presence of infection. Our results confirmed this concept as we demonstrated that a specific
breath pattern of ECOPD distinguishable from stable COPD by classification success ratio of
Table 4. Success ratio and pattern of stimulated sensors when comparing two different species of
bacteria in the breath samples of infected patients.
Analysis % of success ratio SLR utilized
PA vs HI 82 21/17; 2/19
PA vs EC 95 2/13; 12/14
CA vs HI 100 14/9; 15/12; 15/16
CA vs EC 90 21/7; 7/10
HI vs EC 100 24/7; 13/1; 22/16
Abbreviations: PA: Pseudomonas aeruginos, HI: Hemophilus inﬂuenzae, EC: Escherichia coli, CA: Candida
doi:10.1371/journal.pone.0135199.t004
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76% in the absence of PPM. Additionally, we demonstrated a significant distinct breath-print
pattern of ECOPD using e-nose and clearly distinguishable from healthy controls. This also
can be explained on the basis that the e-nose can clearly differentiate the COPD as a chronic
inflammatory airway disease [5, 21] with special breath pattern from others. Also, Fens et al
[27] and Dragonieri et al [36] discriminated COPD from asthma and from non-small cell can-
cer with accuracy of 96% and 85% respectively.
Interestingly, we demonstrated a specific breath pattern for infected ECOPD versus non-
infective episodes with a classification success ratio of 75%. This pattern can be due to firstly
the intensive airway inflammatory response and oxidative stress associated with bacterial infec-
tion in ECOPD [37, 38] that could be a direct cause of specific VOCs breath pattern easily
detectable by the e-nose. Secondly, the e-nose technology is able to identify bacterial pathogens
[19, 20]. This is supported by the recent results demonstrated by our previous pilot study [21]
as breath-print for bacterial colonized COPD was differentiated from non-colonized with accu-
racy of 89%. Also, it may explain the inability of the e-nose to differentiate colonized stable
patients from acutely infected during exacerbation in our analysis.
Further, the breath pattern of ECOPD was distinct from those presented with associated
pneumonia either in case of positive PPM (classification success ratio of 88%) or not (classifica-
tion success ratio of 86%) indicating two different acute events with higher inflammatory
response in case of pneumonia [39].
According to our results, different bacterial species were clearly discriminated in vitro which
was previously demonstrated by Dutta et al [19] and Pavlou et al [20]. Moreover, in COPD
patients, the e-nose technology could differentiate between two different groups of bacteria in
the exhaled breath samples using SLR; as Pseudomonas aeruginosa versus Hemophilus influen-
zae could be discriminated with excellent success ratio. Joensen et al [40] could differentiate
cystic fibrosis patients colonized with Pseudomonas aeruginosa and failed to differentiate
patients colonized with other pathogens. However, there was no clear link between the in vitro
sensitive sensors used for detection of bacterial species and in vivo detection except partially for
Hemophilus influenza. This could be due to high complexity of the exhaled breath which could
be affected by various factors as diet, medications, endogenous metabolism, metabolism by
concomitant resident and pathogen microorganisms as well as varies airway inflammatory pro-
cess accompanied the ECOPD [6, 34, 35].
Clinical implications
Our results showed that the e-nose is able to discriminate a specific exhaled breath pattern
for severe ECOPD-compared to healthy control, stable COPD and COPD with pneumonia-
using a noninvasive, handheld, well tolerated and rapid novel technique. Although it is not
specific enough to guide antibiotic therapy, it has the potential to become a diagnostic tool
for ECOPD associated to bacterial infection in daily clinical practice rather than being
dependent on symptomatic diagnosis [3, 4]. Further, our study shows the ability of the e-
nose to identified the infective ECOPD as well as COPD with pneumonia which help in the
decision of starting antibiotics rather than being empirical or depending on the severity of
exacerbation [41]. This will guard against the emergence of multidrug resistance and modu-
late the economic burden of antibiotic therapy on one hand and different biomarkers for
diagnosing bacterial infection as a cause for ECOPD or guidance of antibiotic therapy [29,
42] on the other hand.
Further studies are needed to determine whether stratification of patients by severity or by
clinical phenotype (i.e. emphysematous/non-emphysematous, frequent exacerbator, COPD/
asthma overlap, etc) are able to reduce the variance of measures.
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Study limitations
Our study has some limitations; firstly, some patients were unable to produce sputum samples
and they were considered as non-infective episodes, which could not be the case, and we
assume that this fact could be responsible for the low specificity found. Further, we did not
consider the variation of the exacerbations’ duration at assessment. Secondly, we did not search
for viral aetiology as a cause of ECOPD [43] or pneumonia in our cohort. However, bacteria
still constitute the commonest cause of ECOPD [7]. Thirdly, we used only Cyranose e-nose as
a diagnostic tool in all our analysis. However, Lai et al [32] and Dutta et al [19] used a similar
device to identify bacterial pathogens in upper respiratory infection. More recently, Joensen et al
[40] and Sibila et al [21] used Cyranose to identify infection in exhaled breath in cystic fibrosis
and colonized stable COPD respectively. Further, technical reproducibility and repeatability of e-
nose measurements was tested previously for Cyranose e-nose by Fens et al [27] and McWilliams
et al [44] with excellent correlation coefficients indicating similar sensor responses. Finally, our
study detected VOCmixtures rather than identifying a specific VOC. Further, we did not mea-
sure inflammation in the sputum which is highly accentuated during ECOPD [6, 34, 35]. In
order to know which compound of VOCs is associate with exacerbations and responsible to
exhaled breath discrimination as well as better identification of inflammation, the application of
other techniques as gas chromatography and mass spectrometry is required.
Conclusions
The e-nose is a well-tolerated, non-invasive, and rapid technique that could be a useful tool to
identify infective ECOPD episodes of bacterial aetiology. Furthermore, it is able to successfully
distinguish ECOPD associated with pneumonia even if microorganism is not cultured. How-
ever, further studies are needed to improve the accuracy in detecting specific micro-organisms
in vivo despite its consistent results in vitro.
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